Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

John Antus

Internal Medicine Manassas, VA Medical Doctor

NPI 1740241314 CMS profile 305723

9306 Forest Point Cir, Manassas, VA 20110

Open in the dashboard

General payments

$3,893

244 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, John Antus of Manassas, VA is reported in the CMS Open Payments database as having received $3,893 across 244 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $15 1
2022 General $612 31
2021 General $853 56
2020 General $1,206 76
2019 General $1,207 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Antus
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Antus were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Antus Internal Medicine median Middle half National median
2019 $1,207 $159 $48–$570 $163
2020 $1,206 $119 $33–$402 $114
2021 $853 $135 $37–$521 $132
2022 $612 $141 $42–$496 $149
2023 $15 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $561 38 payments
  2. Amgen Inc. $470 28 payments
  3. Pfizer Inc. $459 32 payments
  4. AstraZeneca Pharmaceuticals LP $384 24 payments
  5. Sunovion Pharmaceuticals Inc. $302 19 payments
  6. Janssen Pharmaceuticals, Inc $289 16 payments
  7. Sanofi-Aventis U.S. LLC $173 11 payments
  8. Merck Sharp & Dohme Corporation $136 8 payments
  9. Novartis Pharmaceuticals Corporation $117 7 payments
  10. Lilly USA, LLC $92 7 payments
  11. Other $911 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,863 243 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2023
  1. Ozempic $497 34 payments
  2. RYBELSUS $387 26 payments
  3. FARXIGA $329 20 payments
  4. Prolia $274 16 payments
  5. XARELTO $263 14 payments
  6. EVENITY $236 14 payments
  7. ELIQUIS $225 17 payments
  8. APTIOM $201 12 payments
  9. Repatha $146 10 payments
  10. JANUVIA $136 8 payments
  11. Other $2,842 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record